dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma
Authors:
- Serendipity Zapanta RinonosSRSerendipity Zapanta Rinonos
- Sean Thomas PiankaSPSean Thomas Pianka
- Terry J. PrinsTPTerry J. Prins
- Blaine S. C. EldredBEBlaine S. C. Eldred
- Linda M. LiauLLLinda M. Liau
- Phioanh Leia NghiemphuPNPhioanh Leia Nghiemphu
- Timothy F. CloughesyTCTimothy F. Cloughesy
- Albert LaiALAlbert Lai
Open Access
- 15 January 2024
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 166 (1) , 129-142
Abstract
Background: Malignant glioma carries a poor prognosis despite current therapeutic modalities. Standard of care therapy consists of surgical resection, fractionated radiotherapy concurrently administered with temozolomide (TMZ), a DNA-alkylating chemotherapeutic agent, followed by adjuvant TMZ. O-6-methylguanine-DNA methyltransferase (MGMT), a DNA repair enzyme, removes alkylated lesions from tumor DNA, thereby promoting chemoresistance. MGMT promoter methylation status predicts responsiveness to TMZ; patients harboring unmethylated MGMT (~60% of glioblastoma) have a poorer prognosis with limited treatment benefits from TMZ. Methods: Via lentiviral-mediated delivery into LN18 glioma cells, we employed deactivated Cas9-CRISPR technology to target the MGMT promoter and enhancer regions for methylation, as mediated by the catalytic domain of the methylation enzyme DNMT3A. Methylation patterns were examined at a clonal level in regions containing Differentially Methylation Regions (DMR1, DMR2) and the Methylation Specific PCR (MSP) region used for clinical assessment of MGMT methylation status. Correlative studies of genomic and transcriptomic effects of dCas9/CRISPR-based methylation were performed via Illumina 850K methylation array platform and bulk RNA-Seq analysis. Results: We used the dCas9/DNMT3A catalytic domain to achieve targeted MGMT methylation at specific CpG clusters in the vicinity of promoter, enhancer, DMRs and MSP regions. Consequently, we observed MGMT downregulation and enhanced glioma chemosensitivity in survival assays in vitro, with minimal off-target effects. Conclusion: dCas9/CRISPR is a viable method of epigenetic editing, using the DNMT3A catalytic domain. This study provides initial proof-of-principle for CRISPR technology applications in malignant glioma, laying groundwork for subsequent translational studies, with implications for future epigenetic editing-based clinical applications.Keywords
Funding Information
- UCLA Jonsson Comprehensive Cancer Center Postdoctoral Research Award (2021FP04)
- UCLA Tumor Biology Postdoctoral Training Program (T32 CA009056)
- UCLA Tumor Cell Biology Predoctoral Training Program (T32 CA009056)
- National Cancer Institute Ruth L. Kirschstein Research Service Award (F30CA247525-01A1)
- UCLA-Caltech Medical Scientist Training Program (NIGMS T32 GM008042)
- U.S. Department of War (CA190604)
- BCURED Foundation (20199389)
- UCLA SPORE in Brain Cancer (NCI P50 CA211015)
This publication has 34 references indexed in Scilit:
- Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcomeNeuro-Oncology, 2013
- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-statusActa Neuropathologica, 2012
- Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cellsJournal of Neurochemistry, 2012
- MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastomaNeuro-Oncology, 2009
- Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant gliomaNeuro-Oncology, 2009
- Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastomaCancer, 2009
- The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivityNeuro-Oncology, 2009
- Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT ActivityJournal of Clinical Oncology, 2008
- Clonogenic assay of cells in vitroNature Protocols, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005